MarketCap
Facebook
X
TelegramAnnual report 2024
added 05-07-2025
Axon Enterprise DPO Ratio 2011-2026 | AXON
Annual DPO Ratio Axon Enterprise
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29.9 | 138 | 36.5 | 31.9 | 34.5 | 42.2 | 34.3 | 22.9 | 40.1 | 38.7 | 44.5 | 43.7 | 48.3 | 36.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 138 | 22.9 | 44.4 |
Quarterly DPO Ratio Axon Enterprise
| 2025-Q1 | 2024-Q4 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.5 | - | - | 47 | 44.5 | 41.3 | - | 23.4 | 45 | 37 | - | 18.4 | 15.6 | 28 | - | 32.3 | 41.5 | 39 | - | 46.6 | 50.5 | 39.9 | - | 35.3 | 38.4 | 29.5 | - | 19.4 | 23.1 | 28.8 | - | 38.7 | 45.7 | 44.3 | - | 34.7 | 41.9 | 46 | - | 44.8 | 50.2 | 45.4 | - | 43.3 | 45.7 | 47.4 | - | 47.4 | 48.5 | 47.1 | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 50.5 | 15.6 | 38.6 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aptorum Group Limited
APM
|
405 | $ 1.06 | -4.5 % | $ 5.78 M |  China |
 |
Aclaris Therapeutics
ACRS
|
887 | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Certara
CERT
|
10.2 | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Celldex Therapeutics
CLDX
|
6.17 K | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Cellectis S.A.
CLLS
|
975 | $ 4.84 | 1.26 % | $ 116 M |  France |
 |
Amphastar Pharmaceuticals
AMPH
|
28.5 | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
54.4 | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
142 | - | -6.81 % | $ 3.04 B | USA |
 |
CorMedix
CRMD
|
216 K | $ 11.63 | -6.81 % | $ 592 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Aytu BioScience
AYTU
|
186 | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | $ 91.93 | -0.63 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |